{"DataElement":{"publicId":"7241620","version":"1","preferredName":"WHO 2016 Classification of Primary Brain Tumor Name","preferredDefinition":"Names of primary brain tumors classified by WHO 2016 Classification.","longName":"WHO2016_PRI_BRTMR_NM","context":"ABTC","contextVersion":"1","DataElementConcept":{"publicId":"7241619","version":"1","preferredName":"WHO Classification of Tumors Primary Brain Neoplasm","preferredDefinition":"A classification of benign and malignant tumors by World Health Organization (WHO) experts based primarily on histologic findings._Occurring first in time or sequence; original; of greatest rank or importance or value._A benign or malignant neoplasm that arises from or metastasizes to the brain.","longName":"5210896v1.0:7241722v1.0","context":"ABTC","contextVersion":"1","ObjectClass":{"publicId":"5210896","version":"1","preferredName":"WHO Classification of Tumors","preferredDefinition":"A classification of benign and malignant tumors by World Health Organization (WHO) experts based primarily on histologic findings.","longName":"C113304","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"WHO Classification of Tumors","conceptCode":"C113304","definition":"A classification of benign and malignant tumors by World Health Organization (WHO) experts based primarily on histologic findings.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2FC19F3A-FB6B-BEEA-E050-BB89AD436723","latestVersionIndicator":"Yes","beginDate":"2016-04-05","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2016-04-05","modifiedBy":"ONEDATA","dateModified":"2016-04-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"7241722","version":"1","preferredName":"Primary Brain Neoplasm","preferredDefinition":"Occurring first in time or sequence; original; of greatest rank or importance or value.:A benign or malignant neoplasm that arises from or metastasizes to the brain.","longName":"C25251:C2907","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Primary","conceptCode":"C25251","definition":"Occurring first in time or sequence; original; of greatest rank or importance or value.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Brain Neoplasm","conceptCode":"C2907","definition":"A benign or malignant neoplasm that arises from or metastasizes to the brain.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A2CAB875-5163-0E0F-E053-F662850A69C6","latestVersionIndicator":"Yes","beginDate":"2020-04-08","endDate":null,"createdBy":"TSESU","dateCreated":"2020-04-08","modifiedBy":"ONEDATA","dateModified":"2020-04-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A2BB5838-FC60-7FE6-E053-F662850A33BE","latestVersionIndicator":"Yes","beginDate":"2020-04-07","endDate":null,"createdBy":"TSESU","dateCreated":"2020-04-07","modifiedBy":"TSESU","dateModified":"2022-07-06","changeDescription":"Created for ABTC 1802 study in Rave. smt","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"7241615","version":"1","preferredName":"WHO 2016 Classification of Primary Brain Tumor Name","preferredDefinition":"Names of WHO 2016 Classification of primary brain tumors.","longName":"7241615v1.0","context":"ABTC","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"65","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Rhabdoid meningioma","valueDescription":"Rhabdoid Meningioma","ValueMeaning":{"publicId":"2838619","version":"1","preferredName":"Rhabdoid Meningioma","longName":"2838619","preferredDefinition":"An uncommon WHO grade III meningioma containing patches or extensive sheets of rhabdoid cells. Rhabdoid cells are rounded tumor cells with eccentric nuclei, often with a prominent nucleolus and prominent inclusion-like eosinophilic cytoplasm comprised of whorled intermediate filaments. Rhabdoid Meningiomas typically display an aggressive clinical course. (Adapted from WHO 2000.) - 2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Rhabdoid Meningioma","conceptCode":"C6909","definition":"A WHO grade III meningioma characterized by the predominant presence of rhabdoid cells forming sheets.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A6485A-B069-B656-E040-BB89AD437D5F","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A2BB4942-212E-7BF9-E053-F662850A0FD0","beginDate":"2020-04-07","endDate":null,"createdBy":"TSESU","dateCreated":"2020-04-07","modifiedBy":"ONEDATA","dateModified":"2020-04-07","deletedIndicator":"No"},{"value":"Pleomorphic xanthoastrocytoma","valueDescription":"Pleomorphic Xanthoastrocytoma","ValueMeaning":{"publicId":"2578698","version":"1","preferredName":"Pleomorphic Xanthoastrocytoma","longName":"2578698","preferredDefinition":"Pleomorphic Xanthoastrocytoma is an astrocytic tumor with a relatively favorable prognosis (WHO grade II) and is typically encountered in children and young adults. It has a superficial location in the cerebral hemispheres and involvement of the meninges. Characteristic features include pleomorphic and lipidized cells expressing GFAP and often surrounded by a reticulin network as well as eosinophilic granular bodies. For lesions with significant mitotic activity (5 or more mitoses per 10 HPF) and/or with areas of necrosis, the designation \"pleomorphic xanthoastrocytoma with anaplastic features\" may be used. (WHO)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pleomorphic Xanthoastrocytoma","conceptCode":"C4323","definition":"A WHO grade 2 astrocytic tumor with a relatively favorable prognosis.  It is characterized by pleomorphic and lipidized cells expressing GFAP often surrounded by a reticulin network and eosinophilic granular bodies. It presents in the superficial cerebral hemispheres and involves the meninges. It typically affects children and young adults.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0077-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-02-03","endDate":null,"createdBy":"MAESKEB","dateCreated":"2005-02-03","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A2BB4942-2139-7BF9-E053-F662850A0FD0","beginDate":"2020-04-07","endDate":null,"createdBy":"TSESU","dateCreated":"2020-04-07","modifiedBy":"ONEDATA","dateModified":"2020-04-07","deletedIndicator":"No"},{"value":"papillary meningioma","valueDescription":"Papillary Meningioma","ValueMeaning":{"publicId":"2838615","version":"1","preferredName":"Papillary Meningioma","longName":"2838615","preferredDefinition":"A rare WHO grade III meningioma defined by the presence of a perivascular pseudopapillary pattern in at least part of the tumor. They are clinically aggressive. (Adapted from WHO 2000.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Papillary Meningioma","conceptCode":"C3904","definition":"A WHO grade III meningioma characterized by the predominance of a perivascular pseudopapillary pattern.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A6485A-AFE7-B656-E040-BB89AD437D5F","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A2BB4942-214D-7BF9-E053-F662850A0FD0","beginDate":"2020-04-07","endDate":null,"createdBy":"TSESU","dateCreated":"2020-04-07","modifiedBy":"ONEDATA","dateModified":"2020-04-07","deletedIndicator":"No"},{"value":"Glioblastoma, IDH-mutant","valueDescription":"Glioblastoma, IDH-Mutant","ValueMeaning":{"publicId":"7241617","version":"1","preferredName":"Glioblastoma, IDH-Mutant","longName":"7241617","preferredDefinition":"A glioblastoma associated with IDH1 or IDH2 gene mutations.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Astrocytoma, IDH-Mutant, Grade 4","conceptCode":"C167335","definition":"IDH-mutant astrocytoma characterized by the presence of necrosis and/or microvascular proliferation or homozygous deletion of CDKN2A and/or CDKN2B genes. The term glioblastoma no longer applies to central nervous system WHO grade 4 IDH-mutant astrocytomas. (WHO 2021)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A2BB4942-215A-7BF9-E053-F662850A0FD0","latestVersionIndicator":"Yes","beginDate":"2020-04-07","endDate":null,"createdBy":"TSESU","dateCreated":"2020-04-07","modifiedBy":"ONEDATA","dateModified":"2020-04-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A2BB4942-2172-7BF9-E053-F662850A0FD0","beginDate":"2020-04-07","endDate":null,"createdBy":"TSESU","dateCreated":"2020-04-07","modifiedBy":"ONEDATA","dateModified":"2020-04-07","deletedIndicator":"No"},{"value":"Anaplastic meningioma","valueDescription":"Anaplastic (Malignant) Meningioma","ValueMeaning":{"publicId":"5043585","version":"1","preferredName":"Anaplastic (Malignant) Meningioma","longName":"5043585","preferredDefinition":"A WHO grade III meningioma characterized by the presence of malignant morphologic features, including malignant cytology and a very high mitotic index (20 or more mitoses per ten high power fields).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anaplastic (Malignant) Meningioma","conceptCode":"C4051","definition":"A WHO grade III meningioma characterized by the presence of malignant morphologic features, including malignant cytology and a very high mitotic index (20 or more mitoses per ten high power fields).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"24332DE1-107A-F0BF-E050-BB89AD4319C0","latestVersionIndicator":"Yes","beginDate":"2015-11-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-11-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A2BB4942-2187-7BF9-E053-F662850A0FD0","beginDate":"2020-04-07","endDate":null,"createdBy":"TSESU","dateCreated":"2020-04-07","modifiedBy":"ONEDATA","dateModified":"2020-04-07","deletedIndicator":"No"},{"value":"anaplastic ganglioglioma","valueDescription":"Anaplastic Ganglioglioma","ValueMeaning":{"publicId":"3249588","version":"1","preferredName":"Anaplastic Ganglioglioma","longName":"3249588","preferredDefinition":"Anaplastic Ganglioglioma (WHO grade III) is a neuroepithelial neoplasm composed of neoplastic, mature ganglion cells and anaplastic glial cells. These anaplastic changes in the glial component and high MIB-1 and TP53 labelling indices may indicate aggressive behavior.  However, the correlation of histological anaplasia with clinical outcome is inconsistent. (Adapted from WHO.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anaplastic Ganglioglioma","conceptCode":"C4717","definition":"A WHO grade III neuroepithelial neoplasm composed of neoplastic, mature ganglion cells and anaplastic glial cells. The anaplastic changes in the glial component and high MIB-1 and TP53 labeling indices may indicate aggressive behavior. However, the correlation of histological anaplasia with clinical outcome is inconsistent. (Adapted from WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6D99025-BF36-DBB4-E040-BB89AD434418","latestVersionIndicator":"Yes","beginDate":"2011-06-29","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-06-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A2BB4942-219B-7BF9-E053-F662850A0FD0","beginDate":"2020-04-07","endDate":null,"createdBy":"TSESU","dateCreated":"2020-04-07","modifiedBy":"ONEDATA","dateModified":"2020-04-07","deletedIndicator":"No"},{"value":"Anaplastic ependymoma","valueDescription":"Anaplastic Ependymoma","ValueMeaning":{"publicId":"3249041","version":"1","preferredName":"Anaplastic Ependymoma","longName":"3249041","preferredDefinition":"Anaplastic Ependymoma (WHO grade III) is a malignant glioma of ependymal origin with accelerated growth and an unfavorable clinical outcome, particularly in children. Anaplastic Ependymomas show high mitotic activity, often accompanied by microvascular proliferation and pseudo-palisading necrosis. (Adapted from WHO.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anaplastic Ependymoma","conceptCode":"C4049","definition":"A WHO grade 3 malignant glioma of ependymal origin with accelerated growth and an unfavorable clinical outcome, particularly in children. It is characterized by high mitotic activity, often accompanied by microvascular proliferation and pseudo-palisading necrosis. (Adapted from WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6CA5E9E-175E-D7DA-E040-BB89AD432E47","latestVersionIndicator":"Yes","beginDate":"2011-06-28","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-06-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A2BB4942-21AF-7BF9-E053-F662850A0FD0","beginDate":"2020-04-07","endDate":null,"createdBy":"TSESU","dateCreated":"2020-04-07","modifiedBy":"ONEDATA","dateModified":"2020-04-07","deletedIndicator":"No"},{"value":"Anaplastic Pleomorphic Xanthoastrocytoma","valueDescription":"Anaplastic Pleomorphic Xanthoastrocytoma","ValueMeaning":{"publicId":"5525097","version":"1","preferredName":"Anaplastic Pleomorphic Xanthoastrocytoma","longName":"5525097","preferredDefinition":"A WHO grade III pleomorphic xanthoastrocytoma characterized by the presence of five or more mitoses per 10 high-power fields. Necrosis may be present. Patients have shorter survival rates when compared to those with WHO grade II pleomorphic xanthoastrocytoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anaplastic Pleomorphic Xanthoastrocytoma","conceptCode":"C129327","definition":"A WHO grade 3 pleomorphic xanthoastrocytoma characterized by the presence of five or more mitoses per 10 high-power fields. Necrosis may be present. Patients have shorter survival rates when compared to those with WHO grade 2 pleomorphic xanthoastrocytoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3F12FE8D-C807-5079-E053-F662850A582D","latestVersionIndicator":"Yes","beginDate":"2016-10-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-10-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A2BB4942-21B9-7BF9-E053-F662850A0FD0","beginDate":"2020-04-07","endDate":null,"createdBy":"TSESU","dateCreated":"2020-04-07","modifiedBy":"ONEDATA","dateModified":"2020-04-07","deletedIndicator":"No"},{"value":"Anaplastic astrocytoma, IDH-wildtype","valueDescription":"Anaplastic Astrocytoma, IDH-Wildtype","ValueMeaning":{"publicId":"5698586","version":"1","preferredName":"Anaplastic Astrocytoma, IDH-Wildtype","longName":"5698586","preferredDefinition":"Anaplastic astrocytoma lacking mutations in IDH1 or IDH2 genes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anaplastic Astrocytoma, IDH-Wildtype","conceptCode":"C129291","definition":"Anaplastic astrocytoma lacking mutations in IDH1 or IDH2 genes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4A2D2B82-B44F-2EE0-E053-F662850A413A","latestVersionIndicator":"Yes","beginDate":"2017-03-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-03-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A2B743C7-6E73-5FDE-E053-F662850A0BE3","beginDate":"2017-03-07","endDate":null,"createdBy":"TSESU","dateCreated":"2020-04-07","modifiedBy":"ONEDATA","dateModified":"2020-04-07","deletedIndicator":"No"},{"value":"Anaplastic astrocytoma, NOS","valueDescription":"Anaplastic Astrocytoma, Not Otherwise Specified","ValueMeaning":{"publicId":"5698584","version":"1","preferredName":"Anaplastic Astrocytoma, Not Otherwise Specified","longName":"5698584","preferredDefinition":"Anaplastic astrocytoma in which there is insufficient information on the IDH genes status.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anaplastic Astrocytoma, Not Otherwise Specified","conceptCode":"C129292","definition":"A central nervous system tumor with morphological features of anaplastic astrocytoma in which there is insufficient information on the IDH genes status.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4A2D2B82-B429-2EE0-E053-F662850A413A","latestVersionIndicator":"Yes","beginDate":"2017-03-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-03-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A2B743C7-6E7D-5FDE-E053-F662850A0BE3","beginDate":"2017-03-07","endDate":null,"createdBy":"TSESU","dateCreated":"2020-04-07","modifiedBy":"ONEDATA","dateModified":"2020-04-07","deletedIndicator":"No"},{"value":"Anaplastic oligoastrocytoma, NOS","valueDescription":"Anaplastic Oligoastrocytoma, Not Otherwise Specified","ValueMeaning":{"publicId":"5698582","version":"1","preferredName":"Anaplastic Oligoastrocytoma, Not Otherwise Specified","longName":"5698582","preferredDefinition":"A diffuse anaplastic glioma characterized by the presence of both an astrocytic and an oligodendroglial component and the absence of information on the IDH genes status.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anaplastic Oligoastrocytoma, Not Otherwise Specified","conceptCode":"C129324","definition":"A central nervous system tumor with morphological features of anaplastic oligoastrocytoma in which there is insufficient information on the IDH genes status.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4A2D2B82-B403-2EE0-E053-F662850A413A","latestVersionIndicator":"Yes","beginDate":"2017-03-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-03-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A2B743C7-6E87-5FDE-E053-F662850A0BE3","beginDate":"2017-03-07","endDate":null,"createdBy":"TSESU","dateCreated":"2020-04-07","modifiedBy":"ONEDATA","dateModified":"2020-04-07","deletedIndicator":"No"},{"value":"Anaplastic oligodendroglioma, NOS","valueDescription":"Anaplastic Oligodendroglioma, Not Otherwise Specified","ValueMeaning":{"publicId":"5698578","version":"1","preferredName":"Anaplastic Oligodendroglioma, Not Otherwise Specified","longName":"5698578","preferredDefinition":"An anaplastic oligodendroglioma in which there is insufficient information on the IDH genes and 1p/19q codeletion status.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anaplastic Oligodendroglioma, Not Otherwise Specified","conceptCode":"C129322","definition":"A central nervous system tumor with morphological features of anaplastic oligodendroglioma in which there is insufficient information on the IDH genes and 1p/19q codeletion status.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4A2D2B82-B3B7-2EE0-E053-F662850A413A","latestVersionIndicator":"Yes","beginDate":"2017-03-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-03-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A2B743C7-6E91-5FDE-E053-F662850A0BE3","beginDate":"2017-03-07","endDate":null,"createdBy":"TSESU","dateCreated":"2020-04-07","modifiedBy":"ONEDATA","dateModified":"2020-04-07","deletedIndicator":"No"},{"value":"Diffuse astrocytoma, IDH-wildtype","valueDescription":"Diffuse Astrocytoma, IDH-Wildtype","ValueMeaning":{"publicId":"5698574","version":"1","preferredName":"Diffuse Astrocytoma, IDH-Wildtype","longName":"5698574","preferredDefinition":"Diffuse astrocytoma lacking mutations in IDH1 or IDH2 genes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Diffuse Astrocytoma, IDH-Wildtype","conceptCode":"C129274","definition":"Diffuse astrocytoma lacking mutations in IDH1 or IDH2 genes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4A2D2B82-B36B-2EE0-E053-F662850A413A","latestVersionIndicator":"Yes","beginDate":"2017-03-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-03-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A2B743C7-6EA5-5FDE-E053-F662850A0BE3","beginDate":"2017-03-07","endDate":null,"createdBy":"TSESU","dateCreated":"2020-04-07","modifiedBy":"ONEDATA","dateModified":"2020-04-07","deletedIndicator":"No"},{"value":"Diffuse astrocytoma, NOS","valueDescription":"Diffuse Astrocytoma, Not Otherwise Specified","ValueMeaning":{"publicId":"5698572","version":"1","preferredName":"Diffuse Astrocytoma, Not Otherwise Specified","longName":"5698572","preferredDefinition":"Diffuse astrocytoma in which there is insufficient information on the IDH genes status.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Diffuse Astrocytoma, Not Otherwise Specified","conceptCode":"C129277","definition":"A central nervous system tumor with morphological features of diffuse astrocytoma in which there is insufficient information on the IDH genes status.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4A2D2B82-B345-2EE0-E053-F662850A413A","latestVersionIndicator":"Yes","beginDate":"2017-03-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-03-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A2B743C7-6EAF-5FDE-E053-F662850A0BE3","beginDate":"2017-03-07","endDate":null,"createdBy":"TSESU","dateCreated":"2020-04-07","modifiedBy":"ONEDATA","dateModified":"2020-04-07","deletedIndicator":"No"},{"value":"Gemistocytic astrocytoma, IDH-mutant","valueDescription":"Gemistocytic Astrocytoma, IDH-Mutant","ValueMeaning":{"publicId":"5698566","version":"1","preferredName":"Gemistocytic Astrocytoma, IDH-Mutant","longName":"5698566","preferredDefinition":"Gemistocytic astrocytoma carrying IDH mutations.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gemistocytic Astrocytoma, IDH-Mutant","conceptCode":"C129272","definition":"Gemistocytic astrocytoma carrying IDH mutations.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4A2D2B82-B2D3-2EE0-E053-F662850A413A","latestVersionIndicator":"Yes","beginDate":"2017-03-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-03-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A2B743C7-6ECD-5FDE-E053-F662850A0BE3","beginDate":"2017-03-07","endDate":null,"createdBy":"TSESU","dateCreated":"2020-04-07","modifiedBy":"ONEDATA","dateModified":"2020-04-07","deletedIndicator":"No"},{"value":"Giant cell glioblastoma","valueDescription":"Giant Cell Glioblastoma","ValueMeaning":{"publicId":"2578703","version":"1","preferredName":"Giant Cell Glioblastoma","longName":"2578703","preferredDefinition":"A rare histological variant of Glioblastoma (WHO grade IV) with a predominance of bizarre, multinucleated giant cells, an occasionally abundant stromal reticulin network and a high frequency of TP53 mutations. (WHO)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Giant Cell Glioblastoma","conceptCode":"C4325","definition":"A rare histological variant of glioblastoma with a predominance of bizarre, multinucleated giant cells, an occasionally abundant stromal reticulin network, and a high frequency of TP53 mutations. (WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-007C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-04-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-04-23","modifiedBy":"ONEDATA","dateModified":"2006-04-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A2B743C7-6ED7-5FDE-E053-F662850A0BE3","beginDate":"2017-03-07","endDate":null,"createdBy":"TSESU","dateCreated":"2020-04-07","modifiedBy":"ONEDATA","dateModified":"2020-04-07","deletedIndicator":"No"},{"value":"Glioblastoma, IDH-wildtype","valueDescription":"Glioblastoma, IDH-Wildtype","ValueMeaning":{"publicId":"5698562","version":"1","preferredName":"Glioblastoma, IDH-Wildtype","longName":"5698562v1.00","preferredDefinition":"A glioblastoma that arises de novo. It is more commonly seen in older patients. Mutations in IDH1 or IDH2 genes are not present.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Glioblastoma, IDH-Wildtype","conceptCode":"C39750","definition":"A glioblastoma that arises de novo. It is more commonly seen in older patients. Mutations in IDH1 or IDH2 genes are not present.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4A2D2B82-B273-2EE0-E053-F662850A413A","latestVersionIndicator":"Yes","beginDate":"2017-03-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-03-07","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A2B743C7-6EEB-5FDE-E053-F662850A0BE3","beginDate":"2017-03-07","endDate":null,"createdBy":"TSESU","dateCreated":"2020-04-07","modifiedBy":"ONEDATA","dateModified":"2020-04-07","deletedIndicator":"No"},{"value":"Glioblastoma, NOS","valueDescription":"Glioblastoma, Not Otherwise Specified","ValueMeaning":{"publicId":"5698560","version":"1","preferredName":"Glioblastoma, Not Otherwise Specified","longName":"5698560","preferredDefinition":"Glioblastoma in which there is insufficient information on the IDH genes status.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Glioblastoma, Not Otherwise Specified","conceptCode":"C129295","definition":"A central nervous system tumor with morphological features of glioblastoma in which there is insufficient information on the IDH genes status.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4A2D2B82-B24D-2EE0-E053-F662850A413A","latestVersionIndicator":"Yes","beginDate":"2017-03-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-03-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A2B743C7-6EF5-5FDE-E053-F662850A0BE3","beginDate":"2017-03-07","endDate":null,"createdBy":"TSESU","dateCreated":"2020-04-07","modifiedBy":"ONEDATA","dateModified":"2020-04-07","deletedIndicator":"No"},{"value":"Gliosarcoma","valueDescription":"Gliosarcoma","ValueMeaning":{"publicId":"2578705","version":"1","preferredName":"Gliosarcoma","longName":"2578705","preferredDefinition":"A rare histological variant of glioblastoma (WHO grade IV) characterized by a biphasic tissue pattern with alternating areas displaying glial and mesenchymal differentiation (WHO).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gliosarcoma","conceptCode":"C3796","definition":"A rare histological variant of glioblastoma (WHO grade IV) characterized by a biphasic tissue pattern with alternating areas displaying glial and mesenchymal differentiation (WHO).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-007E-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-04-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-04-23","modifiedBy":"COOPERM","dateModified":"2017-03-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A2B743C7-6EFF-5FDE-E053-F662850A0BE3","beginDate":"2017-03-07","endDate":null,"createdBy":"TSESU","dateCreated":"2020-04-07","modifiedBy":"ONEDATA","dateModified":"2020-04-07","deletedIndicator":"No"},{"value":"Oligoastrocytoma, NOS","valueDescription":"Oligoastrocytoma, Not Otherwise Specified","ValueMeaning":{"publicId":"5698558","version":"1","preferredName":"Oligoastrocytoma, Not Otherwise Specified","longName":"5698558","preferredDefinition":"A diffuse glioma characterized by the presence of both an astrocytic and an oligodendroglial component and the absence of information on the IDH genes status.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oligoastrocytoma, Not Otherwise Specified","conceptCode":"C129323","definition":"A central nervous system tumor with morphological features of oligoastrocytoma in which there is insufficient information on the IDH genes status.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4A2D2B82-B21D-2EE0-E053-F662850A413A","latestVersionIndicator":"Yes","beginDate":"2017-03-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-03-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A2B743C7-6F09-5FDE-E053-F662850A0BE3","beginDate":"2017-03-07","endDate":null,"createdBy":"TSESU","dateCreated":"2020-04-07","modifiedBy":"ONEDATA","dateModified":"2020-04-07","deletedIndicator":"No"},{"value":"Oligodendroglioma, IDH-mutant and 1p/19q-codeleted","valueDescription":"Oligodendroglioma, IDH-Mutant and 1p/19q-Codeleted","ValueMeaning":{"publicId":"5698556","version":"1","preferredName":"Oligodendroglioma, IDH-Mutant and 1p/19q-Codeleted","longName":"5698556","preferredDefinition":"An oligodendroglioma carrying IDH gene family mutation and combined whole-arm losses of 1p and 19q (1p/19q codeletion).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oligodendroglioma, IDH-Mutant and 1p/19q-Codeleted","conceptCode":"C129318","definition":"An oligodendroglioma carrying IDH gene family mutation and combined whole-arm losses of 1p and 19q (1p/19q codeletion).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4A2D2B82-B1F7-2EE0-E053-F662850A413A","latestVersionIndicator":"Yes","beginDate":"2017-03-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-03-07","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A2B743C7-6F13-5FDE-E053-F662850A0BE3","beginDate":"2017-03-07","endDate":null,"createdBy":"TSESU","dateCreated":"2020-04-07","modifiedBy":"ONEDATA","dateModified":"2020-04-07","deletedIndicator":"No"},{"value":"Oligodendroglioma, NOS","valueDescription":"Oligodendroglioma, Not Otherwise Specified","ValueMeaning":{"publicId":"5698554","version":"1","preferredName":"Oligodendroglioma, Not Otherwise Specified","longName":"5698554","preferredDefinition":"An oligodendroglioma in which there is insufficient information on the IDH genes and 1p/19q codeletion status.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oligodendroglioma, Not Otherwise Specified","conceptCode":"C129319","definition":"A central nervous system tumor with morphological features of oligodendroglioma in which there is insufficient information on the IDH genes and 1p/19q codeletion status.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4A2D2B82-B1D1-2EE0-E053-F662850A413A","latestVersionIndicator":"Yes","beginDate":"2017-03-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-03-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A2B743C7-6F1D-5FDE-E053-F662850A0BE3","beginDate":"2017-03-07","endDate":null,"createdBy":"TSESU","dateCreated":"2020-04-07","modifiedBy":"ONEDATA","dateModified":"2020-04-07","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2229718","version":"1","preferredName":"Name","preferredDefinition":"The words or language units by which a thing is known.","longName":"C42614","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Name","conceptCode":"C42614","definition":"The words or language units by which a thing is known.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F6EF4E2B-76AE-72C1-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-16","endDate":null,"createdBy":"MAESKEB","dateCreated":"2005-05-16","modifiedBy":"ONEDATA","dateModified":"2005-05-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A2B743C7-6E5D-5FDE-E053-F662850A0BE3","latestVersionIndicator":"Yes","beginDate":"2020-04-07","endDate":null,"createdBy":"TSESU","dateCreated":"2020-04-07","modifiedBy":"TSESU","dateModified":"2022-06-24","changeDescription":"Created for ABTC-1801 smt","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"4280691","version":"1","longName":"CRF CDEs","context":"ABTC","ClassificationSchemeItems":[{"publicId":"4280696","version":"1","longName":"Baseline Evaluations","context":"ABTC"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"WHO 2016 Classification of Pr","type":"Preferred Question Text","description":"WHO 2016 Classification of Primary Brain Tumor Name","url":null,"context":"ABTC"}],"origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A2BB71CA-ABDC-7C89-E053-F662850A9973","latestVersionIndicator":"Yes","beginDate":"2020-04-07","endDate":null,"createdBy":"TSESU","dateCreated":"2020-04-07","modifiedBy":"TSESU","dateModified":"2022-07-07","changeDescription":"Created for ABTC 1802 - smt","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}